July 14/2015 Top StoryFour Launch Mistakes — and How to Avoid Them In the white heat of a major brand launch, pharma companies can become consumed by the day-to-day challenges and make mistakes. But some of the worst mistakes can be avoided with a little foresight, writes Ken Begasse .../ Read more / |
||||||||||
| sponsored Breaking through the complexity Join Dean Summerfield, Senior Vice President, Commercial and Consulting from Quintiles and Dr Jason Lester, Consultant Clinical Oncologist at the Velindre Cancer Centre as they discuss improving innovative oncology treatment and access in the UK ... |
||||||||||
| Leadership Pharm Exec’s Emerging Pharma Leaders 2015 This year’s group of Emerging Pharma Leaders adds to a list of more than 200 alumni dating back to June 2008. We called that first cohort of leaders “the change generation” and the description remains apt today. What is different is a greater diversity in leader backgrounds and the skills required to advance to the “c-suite” .../ Click here for the slide show / |
||||||||||
| sponsored Patient adherence in Germany - benefit vs. cost-containment On DemandJoin Joanne Thiele, Market Access Project Manager from Quintiles Germany and Hans Holger Bleβ, Director of Health Services Research department at IGES Institut GmbH as they discuss the importance of patient adherence programs in Germany ... |
||||||||||
| Europe Joint Procurement of Medicines Climbs the EU Agenda Ireland’s signing of a vaccine procurement agreement last month gives it membership of a growing club of EU member states who are interested in working together to purchase vaccines, writes Reflector .../ Read more / |
||||||||||
| Europe Europe Needs New Timeline for IDMP Implementation All indications are that the July 2016 deadline for transition from Europe’s eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) to the new Identification of Medicinal Products (IDMP) is not achievable. Sophie Daniels reports .../ Read more / |
||||||||||
| Investment Pharma’s Trillion-Dollar Sales Trophy: Will Payers Pony Up? A combination of factors – strong science, internal asset management efficiencies, risk tolerant regulators and willing patients – are pushing the biopharma business toward a fresh landmark: $1 trillion in global sales by 2020. That’s the finding from market analytics firm EvaluatePharma’s “World Preview 2015 — Outlook to 2020”. William Looney looks at the report’s predictions .../ Read more / |
||||||||||
industry update
|
 |
|
 |
|
|
|
 |
 |
 |
 |
 |
 |